Co-administered anionic drugs in the gastrointestinal tract

Co-administered anionic drugs in the gastrointestinal tract do not represent a single biological target, but rather a class of pharmacological entities involved in significant drug-drug interactions. These drugs, which carry a negative charge at physiological pH, are susceptible to binding by cationic agents such as bile acid sequestrants (e.g., cholestyramine) within the gut lumen. This interaction is characterized by the formation of non-absorbable complexes, which prevents the anionic drug from entering systemic circulation. Clinical management of this interaction typically requires careful timing, often necessitating that the anionic drug be administered several hours before or after the binding agent. Common examples of affected medications include anticoagulants like warfarin, thyroid hormones, and various diuretics. Failure to account for these interactions can lead to sub-therapeutic dosing and loss of disease control, making it a critical consideration in polypharmacy and gastrointestinal pharmacology.

Other names

Anionic drugsNegatively charged drugsGastrointestinal drug-drug interactionsSequestrant-bound drugs

The mechanism involves the physical adsorption or ionic binding of negatively charged (anionic) drug molecules to cationic exchange resins or other binding agents within the lumen of the gastrointestinal tract. This binding forms an insoluble complex that cannot be absorbed across the intestinal epithelium, significantly reducing the bioavailability and therapeutic efficacy of the co-administered drug.